2014-12-02 21:02:30 UTC

Probiotic VSL#3 Reduces Liver Disease Severity and Hospitalization in Patients With Cirrhosis

Dec. 4, 2014

Reporting in Gastroenterology, Radha K. Dhiman and colleagues find that, over a six-month period, daily intake of the probiotic VSL#3 significantly improved liver function and reduced the risk of hospitalization for hepatic encephalopathy (HE).

Little is known about whether probiotics can affect outcomes of patients with cirrhosis and hepatic encephalopathy (HE). Radha K. Dhiman and colleagues assessed the efficacy of a probiotic preparation in preventing the recurrence of HE (primary outcome) and reducing the number of hospitalizations and severity of liver disease in patients with cirrhosis. Reporting in Gastroenterology, they find that, over a six-month period, daily intake of VSL#3 significantly reduced the risk of hospitalization for HE, as well as Child–Turcotte–Pugh and model for end-stage liver disease scores, in patients with cirrhosis.

Gastroenterology 2014: 147(6): 1327-1337.e3

More on Cirrhosis

Blog: Special 15th Anniversary Collection from Clinical Gastroenterology and Hepatology

Oct. 11, 2017

Celebrate this milestone with a look back at landmark articles, commentaries and reviews. Read more on the AGA Journals blog.

Spotlight on Fellow-Led Quality Improvement Projects

Oct. 3, 2017

These 19 projects presented at DDW® 2017 showcase the extensive work being done by fellows to improve the quality of care provided to GI patients.

Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents

Oct. 1, 2017

Among HCV-infected patients treated with DAAs, SVR is associated with a considerable reduction in the risk of HCC; however, the risk for HCC remained high in patients with cirrhosis at the time of SVR.